SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences.
Event: Cantor Fitzgerald Future of Oncology Virtual Symposium
Format: Panel Discussion
Date: Monday, April 3, 2023
Time: 11:00am ET
Event: 22nd Annual Needham Virtual Healthcare Conference
Format: Presentation and 1x1 Investor Meetings
Date: Monday, April 17, 2023
Time: 12:45pm ET
Webcast: https://wsw.com/webcast/needham129/cdtx/2262858
Cidara’s presentation at the Needham Conference will be available on-demand from the above date/time in the investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including drug-Fc conjugates (DFCs) from its proprietary Cloudbreak® platform targeting oncologic and viral diseases. In addition, Cidara recently received FDA approval for REZZAYO™ (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
Veronica Eames
LifeSci Communications
(646) 970-4682
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$110.64 |
| Daily Change: | -5.51 -4.74 |
| Daily Volume: | 611,223 |
| Market Cap: | US$2.810B |
October 13, 2025 October 09, 2025 September 25, 2025 September 24, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
